Bora Pharmaceuticals Announces Guarantee Balance to Subsidiary Reaches Article 25, Paragraph 1, Subparagraph 3 of the 'Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies'
Bora Pharmaceuticals announced that its endorsement/guarantee balance for its subsidiary, Upsher-Smith Laboratories, LLC, has reached the threshold specified in Article 25, Paragraph 1, Subparagraph 3 of the 'Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies'. The company newly provided a credit line guarantee for the subsidiary.
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 09:00
- 🔍 Collected: May 14, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 14, 2026 at 08:25 (24 min after Collected)
1. Date of occurrence of the event: 115/05/13
2. Company under endorsement/guarantee:
(1) Company name: Upsher-Smith Laboratories, LLC
(2) Relationship with the company providing endorsement/guarantee:
A 100% indirectly held subsidiary of the Company
(3) Limit of endorsement/guarantee (in thousands of NTD): 72,844,305
(4) Original endorsement/guarantee balance (in thousands of NTD): 157,575
(5) Amount of new endorsement/guarantee (in thousands of NTD): 630,300
(6) Endorsement/guarantee balance up to the date of occurrence (in thousands of NTD): 787,875
(7) Actual amount used by the company under endorsement/guarantee (in thousands of NTD): 0
(8) Reason for new endorsement/guarantee: The Company provides a credit line guarantee for its subsidiary
3. Collateral provided by the company under endorsement/guarantee:
(1) Content: None
(2) Value (in thousands of NTD): 0
4. Latest financial statements of the company under endorsement/guarantee:
(1) Capital (in thousands of NTD): 31,280,096
(2) Accumulated profit/loss (in thousands of NTD): -24,296,954
5. Conditions for lifting endorsement/guarantee responsibility:
(1) Conditions: According to contractual terms
(2) Date: According to contractual terms
6. Total limit of endorsement/guarantee (in thousands of NTD): 72,844,305
7. Endorsement/guarantee balance up to the date of occurrence (in thousands of NTD): 11,393,548
8. Ratio of the endorsement/guarantee balance provided by A to the net worth of the public company's latest financial statements as of the date of occurrence: 78.20%
9. Ratio of the total balance of endorsement/guarantee, long-term investments, and funds loaned to the net worth of the public company's latest financial statements as of the date of occurrence: 65.11%
10. Other matters that should be specified: None
2. Company under endorsement/guarantee:
(1) Company name: Upsher-Smith Laboratories, LLC
(2) Relationship with the company providing endorsement/guarantee:
A 100% indirectly held subsidiary of the Company
(3) Limit of endorsement/guarantee (in thousands of NTD): 72,844,305
(4) Original endorsement/guarantee balance (in thousands of NTD): 157,575
(5) Amount of new endorsement/guarantee (in thousands of NTD): 630,300
(6) Endorsement/guarantee balance up to the date of occurrence (in thousands of NTD): 787,875
(7) Actual amount used by the company under endorsement/guarantee (in thousands of NTD): 0
(8) Reason for new endorsement/guarantee: The Company provides a credit line guarantee for its subsidiary
3. Collateral provided by the company under endorsement/guarantee:
(1) Content: None
(2) Value (in thousands of NTD): 0
4. Latest financial statements of the company under endorsement/guarantee:
(1) Capital (in thousands of NTD): 31,280,096
(2) Accumulated profit/loss (in thousands of NTD): -24,296,954
5. Conditions for lifting endorsement/guarantee responsibility:
(1) Conditions: According to contractual terms
(2) Date: According to contractual terms
6. Total limit of endorsement/guarantee (in thousands of NTD): 72,844,305
7. Endorsement/guarantee balance up to the date of occurrence (in thousands of NTD): 11,393,548
8. Ratio of the endorsement/guarantee balance provided by A to the net worth of the public company's latest financial statements as of the date of occurrence: 78.20%
9. Ratio of the total balance of endorsement/guarantee, long-term investments, and funds loaned to the net worth of the public company's latest financial statements as of the date of occurrence: 65.11%
10. Other matters that should be specified: None